Literature DB >> 10741291

Federation of European Cancer Societies. Full report. Economic evaluation in cancer care: questions and answers on how to alleviate conflicts between rising needs and expectations and tightening budgets.

E van der Schueren1, K Kesteloot, I Cleemput.   

Abstract

All Western countries have experienced a fast growth in their healthcare expenses over recent decades. It is expected that pressure for such growth will continue in the future. But spending an ever larger share of our nation's resources on healthcare cannot be afforded. As a consequence, making choices will become more and more inevitable, even in cancer care. Economic evaluation is a very supportive tool for such decisions. This position statement concludes with recommendations for providers and healthcare policy-makers, to safeguard and further improve good clinical decision making and healthcare policy in cancer care under tightening budgets.

Entities:  

Mesh:

Year:  2000        PMID: 10741291     DOI: 10.1016/s0959-8049(99)00242-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  2 in total

1.  From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.

Authors:  Samuel Limat; Marie-Christine Woronoff-Lemsi; Céline Menat; Anne Madroszyk-Flandin; Yacine Merrouche
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Feasibility study of multidisciplinary oncology rounds by videoconference for surgeons in remote locales.

Authors:  Anna Gagliardi; Andy Smith; Vivek Goel; Denny DePetrillo
Journal:  BMC Med Inform Decis Mak       Date:  2003-06-19       Impact factor: 2.796

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.